Loading company…
Renasant Bio develops small molecule therapies for autosomal dominant polycystic kidney disease.
Based in Berkeley, US, Renasant Bio develops therapies for autosomal dominant polycystic kidney disease (ADPKD). Its small molecule correctors and potentiators target the renal proteins polycystin 1 and 2. In July 2025, it raised USD 54.5 mn in Seed funding co-led by 5AM Ventures, Atlas Venture, OrbiMed Advisors, and Qiming Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in